Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma

NCT03149822 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Cabozantinib
DRUG: Pembrolizumab

Sponsor

University of Colorado, Denver

Collaborators

[object Object]